XML 24 R12.htm IDEA: XBRL DOCUMENT v3.26.1
Inventories
 6 Months Ended
Jun. 30, 2026
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consist of the following (in thousands):
June 30,
2026		December 31,
2025
Work-in-progress$16,679 $12,524 
Finished goods1,682 1,894 
Inventories$18,361 $14,418 
As of June 30, 2026 and December 31, 2025, the company had $0.6 million and $1.1 million, respectively, of inventory on hand that was produced prior to regulatory approvals. This inventory was expensed in research and development expense on the condensed consolidated statements of operations, as the future economic benefit was not probable. We began capitalizing inventory costs associated with ANKTIVA after receiving FDA approval in April 2024 when it was determined that the inventory had a probable future economic benefit. Inventory that is used for clinical development purposes is expensed in research and development expense, on the condensed consolidated statement of operations when consumed. The company’s long-term inventories, net consist of work-in-process and finished goods that are expected to be sold or consumed beyond 12 months.
As of June 30, 2026 and December 31, 2025, the allowance for inventory reserve was $0.2 million.